NCT07898436Recruiting
Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia
Management of Relapsed or Refractory Acute Leukemia With Menin Inhibitors in Children: A French National Retrospective Study
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Acute leukemia is the most common childhood cancer. Despite advances in targeted therapies and immunotherapies, treatment remains challenging for children with relapsed or refractory acute leukemia, particularly those with KMT2A rearrangements, NPM1 mutations, or NUP98 rearrangements. Menin inhibitors have shown promising antileukemic activity in these molecular subgroups. This French national, multicenter, retrospective observational study will describe the pediatric population treated with menin inhibitors for relapsed or refractory acute leukemia. Clinical and biological data will be collected from the SACHA database for patients treated between February 1, 2020, and July 31, 2026. Approximately 10 patients are expected to be included. The study will describe patient and disease characteristics, treatment administration, safety, and efficacy, including remission status, minimal residual disease, relapse, and overall survival.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10 (estimated)
- First submitted
- 20 Oct 2026
- Start date
- 8 Sept 2026
- Primary completion date
- 8 Jan 2027
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Childhood cancers
- NCT number
- NCT07898436
What you commit to
- Study type: Observational
- Planned participants: 10
- From 8 Sept 2026 to the primary completion date, 8 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received a Temporary Authorization for Use (ATU) but did not receive the treatment.
Who the study is looking for
- Patients with relapsed or refractory acute leukemia eligible for menin inhibitor treatment because of a KMT2A or NUP98 rearrangement or an NPM1 mutation.
- Patients who received menin inhibitor treatment under a Temporary Authorization for Use (ATU).
- Patients younger than 18 years at the time of acute leukemia diagnosis.
- Patients who have not objected to the reuse of their data for scientific research.
- Patients whose holders of parental authority have already provided authorization for the reuse of the child's data for scientific research.
Age in the registry: 0 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de Pédiatrie 3 - Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg - France Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.